(Date:12/10/2009)... Corporation (Nasdaq: DNDN ) announced today that it ... of its common stock at a price to the ... to the underwriters a 30-day option to purchase up ... cover overallotments, if any. The offering is expected ... closing conditions. ,, J. P. Morgan Securities Inc. and ...
(Date:12/10/2009)... Institute (NEI), a division of the National Institutes of Health ... help fund its development of a non-invasive, passive diffusion-based treatment ... ... Salt Lake City, UT (PRWEB) December 10, 2009 ... National Institutes of Health (NIH), awarded a $2.18 million grant ...
(Date:12/10/2009)... 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... product development company that identifies and advances a ... stages of development, today provided an update on ... merger of Cytopia Ltd. into YM, details of ... board of directors of Cytopia has unanimously recommended ...
(Date:12/10/2009)... Vivakor, Inc. (OTC Bulletin Board: ... into an exclusive, $5 million license agreement ... ( www.regeneca.com ). The agreement exclusively ... new cutting-edge nutraceutical formulation developed by Vivakor ... formulations by Vivakor for Regeneca. Under the ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3... Abaxis, Inc. (Nasdaq: ABAX ), ... instruments for both the medical and veterinary markets, ... license agreement for co-exclusive worldwide rights in the ... marketplace for certain technologies pertaining to lateral flow ...
... Jan. 7 Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA: ... NASDAQ Listing Qualifications Panel has granted CTI,s request to ... Global Market to The NASDAQ,Capital Market, which will be ... 2009. CTI,s shares will continue to trade under the ...
... PALO ALTO, Calif., Jan. 6 Cell Biosciences, ... science researchers, today,announced the placement of a next-generation ... the Stanford University School of,Medicine. ... Monitoring,Center (HIMC) at Stanford , will analyze ...
Other Biology Technology:ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 2ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology 3Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 2Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 3Cell Biosciences Delivers Next Generation System to Stanford University 2LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Quality ISO 9001:2000 Certified USDA ... Precedures Validated, SOP's Training AALAS ... for All Procedures GLP Documentation Upon Request ... stop shopping point for all your custom ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products:Biology NavigationMedical Navigation